2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

11:00AM-12:30PM: Abstract Number: 2994

Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2948

Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2964

Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2959

Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2962

Diagnostic Accuracy of Gout in Electronic Health Records and the Role of Rheumatology Electronic Consults

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2961

Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Providers from 2010 to 2018

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2953

Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2990

Do Polymyalgia Rheumatica Patients Have an Increased Risk of Cardiovascular Events?: A Matched-Control Study

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

11:00AM-12:30PM: Abstract Number: 2999

Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2960

Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2954

Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2995

Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2976

Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2963

Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2970

In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].